Background The growing body of evidence indicating the heterogeneity of Alzheimer's
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …

Neurodegenerative diseases are a major burden for our society, affecting millions of people
worldwide. A main goal of past and current research is to enhance our understanding of the …

Alzheimer's disease is the most common form of dementia, characterized by a persistent and
progressive impairment of cognitive functions. Alzheimer's disease is typically associated …

The brain-specific enzyme CYP46A1 controls cholesterol turnover by converting cholesterol
into 24 S-hydroxycholesterol (24OH). Dysregulation of brain cholesterol turnover and …

Neuronal endosomal dysfunction, the earliest known pathobiology specific to Alzheimer's
disease (AD), is mediated by the aberrant activation of Rab5 triggered by APP-β secretase …

The loss of excitatory synapses is known to underlie the cognitive deficits in Alzheimer's
disease (AD). Although much is known about the mechanisms underlying synaptic loss in …

It is well established that GluA1 mediated synaptic plasticity plays a central role in the early
development of AD. The complex cellular and molecular mechanisms that enable GluA1 …

Pathogenic processes underlying Alzheimer's disease (AD) affect synaptic function from
initial asymptomatic stages, long time before the onset of cognitive decline and …

Alzheimer's disease (AD) is the most common progressive and irreversible
neurodegeneration characterized by the impairment of memory and cognition. Despite years …

Cannabidiol (CBD), a phytocannabinoid from the Cannabis sativa plant, exhibits a broad
spectrum of potential therapeutic properties for neurodegenerative diseases. An …